NCT07919678ClinicalTrials.gov
A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-MONTHLY BEROBENATIDE IN ADULTS WITH KNEE OSTEOARTHRITIS AND OVERWEIGHT OR OBESITY (VESPER-OA 1)
Kurz gefasst
The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity. The study will last 52 weeks and compare the effects of…
Phase 3656 Teilnehmende gesucht40 Studienzentren2 Länder
Kategorien
In 1 Register registriert
- ClinicalTrials.govNCT07919678Diesen Eintrag bei ClinicalTrials.gov öffnenSynchronisiert vor 2 Wochen
Eine Studie kann in mehreren Registern registriert sein. Wir zeigen sie einmal und verlinken jeden Eintrag, den wir haben.
Die Studieninformationen werden so angezeigt, wie sie vom Register veröffentlicht wurden, in ihrer Originalsprache.
Interesse an dieser Studie?
Anmelden oder ein Konto erstellen um Ihr Interesse zu bekunden und diese Studie zu verfolgen.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Not stated: Registered after enrolment began (about 10 days after the recorded start)First posted 2026-11-05; recorded start 2026-10-26
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 635 other studies in this databaseCounted from the lead sponsor named in the record (Pfizer)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 3 conditions.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm13/15
Placebo / sham control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 40 sites
- Data monitoring committee7/7
A data monitoring committee is in place
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study, international in scope: 656 participants (target), run at 40 sites, across 2 countries.
How this score is built
- Enrolment28/40
656 participants (target)
- Site count19/25
40 sites
- Country count7/15
2 countries
- Planned duration7/10
Planned over about 24 months
- Sponsor scale10/10
Pfizer has led 630 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Zusammenfassung
The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity. The study will last 52 weeks and compare the effects of berobenatide compared to placebo on knee pain, physical function, and body weight. Study activities will include blood tests, knee pain assessment, physical function questionnaires and body measurements.
Erkrankungen
- Obesity
- Overweight
- Osteoarthritis of the Knee
Eignung
| Geschlecht | Alle |
|---|---|
| Alter | 18 Years – Kein Höchstalter |
| Gesunde Freiwillige | Nein |
Eignung im Wortlaut des Registers
Eignung in einfachen Aussagen
Die Kriterien dieses Eintrags wurden noch nicht in einzelne Aussagen aufgeschlüsselt. Der Registertext oben ist vollständig und ist die maßgebliche Fassung.
Studiendesign
| Studientyp | Interventionell |
|---|---|
| Phase | Phase 3 |
| Zuteilung | Randomisiert |
| Interventionsmodell | PARALLEL |
| Primäres Ziel | TREATMENT |
| Verblindung | QUADRUPLE (4) |
| Teilnahme | 656 Teilnehmende gesucht |
Sponsor und Mitwirkende
- Pfizer Sponsor
Studienarme und Interventionen
- PlaceboPLACEBO_COMPARATOR
Participants will receive placebo as subcutaneous injection
- Arm 1: Berobenatide Once MonthlyEXPERIMENTAL
Participants will receive berobenatide by subcutaneous injection.
- Arm 2: Berobenatide Once MonthlyEXPERIMENTAL
Participants receive berobenatide by subcutaneous injection.
- Arm 3: Berobenatide Once MonthlyEXPERIMENTAL
Participants receive berobenatide by subcutaneous injection.
Interventionen
- Arzneimittel Berobenatide
Subcutaneous Injection
- Sonstige Placebo
Subcutaneous Injection
Endpunkte
Primärer Endpunkt
Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale score
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Percent change from baseline in Body Weight
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Change From Baseline in High-Sensitivity C-Reactive Protein
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Change from baseline in WOMAC Physical Function Subscale score
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Percentage of participants with ≥50% reduction in the WOMAC pain subscale score
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Percentage of participants with ≥30% reduction in the WOMAC pain subscale score
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Proportion of participants with utilization of protocol specified pain medication during the washout period
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Amount of protocol specified pain medication during the washout period
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Change from baseline in WOMAC stiffness score
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Change from baseline in WOMAC total score
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Proportion of participants achieving ≥50% reduction in the WOMAC physical function subscale score
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Proportion of participants meeting OMERACT-OARSI
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Change from baseline in Average Pain Intensity-Numerical Rating Score
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Change from baseline in Worst Pain Intensity -Numerical Rating Score
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Change from baseline in SF-36 domain scales and component summary scales
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Change from baseline in Body Weight
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Change from Baseline in Body Mass Index
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Number of participants with Treatment Emergent Adverse Events (TEAEs)
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Number of Participants with Serious Adverse Events (SAE)
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Number of Participants with AE leading to permanent discontinuation from study intervention or study
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Number of Participants with Adverse Events of Special Interest (AESI)
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Number of Participants with Clinical laboratory abnormalities
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Change from baseline in timed walking distance at Week 52
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Percentage of Participants Reporting Improvement in Patient Global Impression of Severity (PGI-S) for knee-OA related physical function
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Percentage of Participants Reporting Improvement in Patient Global Impression of Severity (PGI-S) for knee-OA pain
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Percentage of Participants Reporting Improvement in Patient Global Impression of Change (PGI-C) for knee-OA related physical function
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Percentage of Participants Reporting Improvement in Patient Global Impression of Change PGI-C for knee-OA pain
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Change From Baseline in EuroQol 5-Dimension, 5-Level (EQ-5D-5L) Index Score
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Change From Baseline in EuroQol-visual analog scale (EQ-VAS) Score
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Change From Baseline in Work Productivity and Activity Impairment - General Health (WPAI:GH) Absenteeism Score
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Change From Baseline in WPAI:GH Work productivity loss score
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Change From Baseline in WPAI:GH Activity impairment score
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Change From Baseline in Systolic Blood Pressure (SBP)
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Change From Baseline in Diastolic Blood Pressure (DBP)
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Change From Baseline in Total Cholesterol
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Change From Baseline in High-density lipoprotein cholesterol (HDL-C)
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Change From Baseline in Low-density lipoprotein cholesterol (LDL-C)
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Change from baseline in Non-HDL Cholesterol
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Change from baseline in Very low-density lipoprotein cholesterol (VLDL) Cholesterol
Zeitrahmen Baseline and Week 52
Sekundärer Endpunkt
Change from baseline in Triglycerides
Zeitrahmen Baseline and Week 52
Daten
| Startdatum | 26. Oktober 2026 (tatsächlich) |
|---|---|
| Primärer Abschluss | 22. August 2028 (geschätzt) |
| Abschluss | 10. Oktober 2028 (geschätzt) |
| Erstveröffentlichung | 5. November 2026 (tatsächlich) |
| Zuletzt aktualisiert | 5. November 2026 |
| Ergebnisse veröffentlicht | Im Registereintrag nicht angegeben |
| Status zuletzt bestätigt | Oktober 2026 |
Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.
Standorte
7 Studienzentren rekrutieren
Canada
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Bluewater Clinical Research Group Inc. | Sarnia | Ontario | Rekrutierung noch nicht begonnen |
United States
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Albuquerque Clinical Trials, Inc. | Albuquerque | New Mexico | Rekrutierung noch nicht begonnen |
| Charlottesville Medical Research Center, LLC | Charlottesville | Virginia | Rekrutierung noch nicht begonnen |
| Northwestern University Feinberg School Of Medicine | Chicago | Illinois | Rekrutierung noch nicht begonnen |
| Great Lakes Clinical Trials, LLC dba Flourish Research | Chicago | Illinois | Rekrutierung noch nicht begonnen |
| Northwestern Medicine | Chicago | Illinois | Rekrutierung noch nicht begonnen |
| Northwestern Memorial Hospital, Diagnostic Testing Center (Phlebotomy/EKG) | Chicago | Illinois | Rekrutierung noch nicht begonnen |
| Northwestern Memorial Hospital, Investigational Drug Service | Chicago | Illinois | Rekrutierung noch nicht begonnen |
| Clinical Research of West Florida, Inc. | Clearwater | Florida | Rekrutierung noch nicht begonnen |
| Skylight Health Research | Colorado Springs | Colorado | Rekrutierung noch nicht begonnen |
| Mercy Family Clinic | Dallas | Texas | Rekrutierung noch nicht begonnen |
| Universal Axon Clinical Research LLC | Doral | Florida | Rekrutiert |
| Altoona Center For Clinical Research | Duncansville | Pennsylvania | Rekrutiert |
| Headlands Research California, LLC | Escondido | California | Rekrutierung noch nicht begonnen |
| Profound Research LLC | Farmington Hills | Michigan | Rekrutiert |
| Cedar Health Research | Fort Worth | Texas | Rekrutierung noch nicht begonnen |
| Novant Health Granite Quarry Internal Medicine (knee x-ray) | Granite Quarry | North Carolina | Rekrutierung noch nicht begonnen |
| BRCR Global Louisiana | Gretna | Louisiana | Rekrutierung noch nicht begonnen |
| JCCT-JUNO NW Houston | Houston | Texas | Rekrutierung noch nicht begonnen |
| Westside Center for Clinical Research | Jacksonville | Florida | Rekrutierung noch nicht begonnen |
| Activian Clinical Research | Kingwood | Texas | Rekrutierung noch nicht begonnen |
| Renstar Medical Research | Lady Lake | Florida | Rekrutierung noch nicht begonnen |
| Monroe Biomedical Research | Monroe | North Carolina | Rekrutiert |
| AMR Clinical | Norman | Oklahoma | Rekrutierung noch nicht begonnen |
| Renstar Medical Research | Ocala | Florida | Rekrutierung noch nicht begonnen |
| Prospective Research Innovations Inc. | Rancho Cucamonga | California | Rekrutierung noch nicht begonnen |
| Accellacare - Salisbury | Salisbury | North Carolina | Rekrutierung noch nicht begonnen |
| Consano Clinical Research, LLC | Shavano Park | Texas | Rekrutierung noch nicht begonnen |
| Revive Research Institute, Inc. | Sterling Heights | Michigan | Rekrutiert |
| Clinical Research Atlanta | Stockbridge | Georgia | Rekrutierung noch nicht begonnen |
| Clinical Research of West Florida, Inc. | Tampa | Florida | Rekrutierung noch nicht begonnen |
| AMR Clinical | Tempe | Arizona | Rekrutierung noch nicht begonnen |
| DM Clinical Research | Tomball | Texas | Rekrutierung noch nicht begonnen |
| Solace Clinical Research | Tustin | California | Rekrutierung noch nicht begonnen |
| Velocity Clinical Research, Waco | Waco | Texas | Rekrutierung noch nicht begonnen |
| Elevate Clinical Research | Wichita | Kansas | Rekrutierung noch nicht begonnen |
| Delaney Radiologist | Wilmington | North Carolina | Rekrutiert |
| Accellacare | Wilmington | North Carolina | Rekrutiert |
| North Georgia Internal Medicine | Woodstock | Georgia | Rekrutierung noch nicht begonnen |
| North Georgia Clinical Research, LLC | Woodstock | Georgia | Rekrutierung noch nicht begonnen |
Studiendokumente
In diesem Registereintrag sind keine Dokumente verlinkt.
Änderungen im Zeitverlauf
Seit wir diesen Eintrag erstmals eingelesen haben, wurden keine Änderungen erfasst.
Eine Änderung wird jedes Mal erfasst, wenn der Sponsor den Registereintrag aktualisiert. Status, Daten, Teilnahme und Studienzentren erscheinen hier, sobald sie sich ändern.